Watch CADL. Know when insiders buy.
One email the day a filing lands. Free.
CADL
Candel Therapeutics, Inc.
12.17
−0.43 −3.41%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $931.2MP/E —DIV YIELD —FCF YIELD -6.16%REV TTM —NET INCOME −$88.5MNET CASH $201M52W 4.42 – 13.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$26.7M | −$38.9M | — | -0.52 | −$17.2M | $69K | −$17.3M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$16.3M | −$8.9M | −220.1% | -0.14 | −$18M | $675K | −$18.7M | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$15.8M | −$29.5M | — | -0.55 | −$10.6M | $409K | −$11M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$13.2M | −$11.3M | — | -0.21 | −$10.2M | $144K | −$10.4M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$11.2M | −$4.8M | — | -0.09 | −$8.9M | $31K | −$8.9M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$8.1M | $7.4M | — | 0.13 | −$8.6M | $3K | −$8.6M | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$8.1M | −$14.1M | — | -0.39 | −$5.8M | $3K | −$5.8M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$8.8M | −$10.6M | — | -0.33 | −$6.6M | $0 | −$6.6M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$8.6M | −$22.2M | — | -0.74 | −$6.2M | $6K | −$6.2M | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$7.9M | −$8.2M | — | -0.28 | −$8.4M | $7K | −$8.4M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.3M | −$11.1M | — | -0.38 | −$7.4M | $47K | −$7.5M | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$8.9M | −$8.4M | — | -0.29 | −$8.8M | $103K | −$8.9M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$48.3M | −$38.2M | — | -0.72 | −$38.3M | $587K | −$38.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$33.4M | −$55.2M | — | -1.74 | −$27M | $16K | −$27M | — | — |
| FY2023 · to Dec 31 | — | — | −$38.4M | −$37.9M | — | -1.31 | −$34.2M | $457K | −$34.7M | — | — |
| FY2022 · to Dec 31 | $125K | — | −$34.7M | −$18.8M | -15035.2% | -0.65 | −$31.4M | $1.3M | −$32.7M | — | — |
| FY2021 · to Dec 31 | $125K | — | −$25.7M | −$36.1M | -28899.2% | -1.91 | −$22.2M | $1.8M | −$24.1M | — | — |
| FY2020 · to Dec 31 | $125K | — | −$13.8M | −$17.7M | -14144.0% | -1.52 | −$9.1M | $1.5M | −$10.5M | — | — |
Every number comes from Candel Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.